Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevention of Female Genital Schistosomiasis (FGS) in Rural High-endemic South Africa (VIBE-FGS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01154907
Recruitment Status : Recruiting
First Posted : July 1, 2010
Last Update Posted : September 19, 2017
Sponsor:
Collaborators:
University of KwaZulu
University of Agder
Sorlandet Hospital HF
University of Copenhagen
Leiden University Medical Center
Universiteit Antwerpen
Information provided by (Responsible Party):
Eyrun Floerecke Kjetland, Oslo University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

Schistosomiasis is a poverty-related water-transmitted parasitic disease affecting more that 200 million people world wide. Infection with Schistosoma haematobium may cause Female Genital Schistosomiasis (FGS) with pathological lesions in the female genital tract, especially the cervix. Findings indicate that FGS is a hitherto under-diagnosed illness of young women in endemic poor tropical countries, deserving further attention. A cross-sectional study from Zimbabwe indicated that the pathologic genital lesions were unchanged two years after praziquantel treatment in adult women whereas in those who had been treated with praziquantel in childhood the prevalence of genital lesions was significantly lower. Furthermore, a higher prevalence of HIV was detected in women with FGS compared to those without. The proposed project aims at achieving a better understanding of how annual distribution of praziquantel to pre- and post-pubertal schoolgirls may prevent FGS. This information can be of use in current schistosomiasis control programs in the near term resulting in improved strategies for treatment. Preventing or reducing the risk of FGS and genital lesions will lead to improved reproductive health among in women living in schistosomiasis endemic areas.

Project Goal: Contribute to a reduction of the global burden of female genital schistosomiasis (FGS) through improved knowledge about the prevention of gynecological lesions and through improved diagnosis of FGS.


Condition or disease Intervention/treatment
Uro-genital Schistosomiasis Drug: Praziquantel

Detailed Description:
Provide a more extensive description, if desired. Avoid duplication of information to be recorded elsewhere, such as eligibility criteria or outcome measures
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 6500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prevention of HIV and Improved Diagnosis of Adolescent Genital Disease in Bilharzia Endemic KwaZulu-Natal, South Africa
Study Start Date : April 2010
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Girls ages 10-12

In 18 rural schools in Ugu District, South Africa. Undergoing mass-treatment provided by the Department of Health.

Praziquantel was administered at 40mg/kg in annual mass-treatment

 Drug: Praziquantel
One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
Other Name: Biltricide
Young adult women

In rural schools in three districts, South Africa. Undergoing mass-treatment provided by the Departments of Health.

Praziquantel was administered at 40mg/kg in annual mass-treatment

 Drug: Praziquantel
One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
Other Name: Biltricide


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. HIV prevalence after anti-schistosomal treatment in adolescents [ Time Frame: 31. December 2021 ]
    HIV prevalence


Secondary Outcome Measures :
  1. FGS prevalence and severity after anti-schistosomal treatment in adolescents [ Time Frame: 31. December 2021 ]
    Clinical disease

  2. Clinical and laboratory indicators of urogenital schistosomiasis [ Time Frame: 31. December 2018 ]
    Polymerase chain reaction (PCR) of vaginal lavage, Cytology, Circulation Anodic Antigen (CAA)


Other Outcome Measures:
  1. Pocket Atlas of Female Genital Schistosomiasis [ Time Frame: 31. December 2015 ]
    Published by WHO in English, French and Portuguese


Biospecimen Retention:   Samples Without DNA
Urine, stool, blood, in the adults also vaginal lavage and Pap smears

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 23 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
A random sample of school girls in Ugu district, KwaZulu Natal, South Africa
Criteria

Inclusion Criteria:

  • Females in Schistosoma haematobium endemic areas

Exclusion Criteria:

  • Boys
  • Pregnancy
  • Allergic to praziquantel
  • Severe disease
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01154907


Contacts
Layout table for location contacts
Contact: Eyrun Floereke Kjetland, MD, PhD +47 97008579 e.f.kjetland@medidin.uio.no
Contact: Myra Taylor, MD, PhD

Locations
Layout table for location information
South Africa
University of KwaZulu Natal Recruiting
Durban, KwaZulu Natal, South Africa, 4000
Contact: Eyrun F. Kjetland, MD, PhD    +27 76 4920800    e.f.kjetland@medisin.uio.no   
Contact: Myra Taylor, MD, PhD    +27 31 2604499    taylor@ukzn.ac.za   
Sub-Investigator: Elisabeth Kleppa, MD         
Sponsors and Collaborators
Oslo University Hospital
University of KwaZulu
University of Agder
Sorlandet Hospital HF
University of Copenhagen
Leiden University Medical Center
Universiteit Antwerpen
Investigators
Layout table for investigator information
Principal Investigator: Eyrun F Kjetland, MD, PhD Oslo University Hospital, University of KwaZulu-Natal (UKZN)
Principal Investigator: Myra Taylor, PhD UKZN/ Child Development Research Unit (CDRU)
Principal Investigator: Jane Kvalsvig, PhD UKZN/ CDRU
Principal Investigator: Svein G Gundersen, MD, PhD Agder University Hospital / Sorlandet Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:

Other Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Eyrun Floerecke Kjetland, MD, Oslo University Hospital
ClinicalTrials.gov Identifier: NCT01154907    
Other Study ID Numbers: VIBE-FGS
First Posted: July 1, 2010    Key Record Dates
Last Update Posted: September 19, 2017
Last Verified: September 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Still collecting and publishing
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Time Frame: December 2021-December 2022
Access Criteria: From endemic country
Keywords provided by Eyrun Floerecke Kjetland, Oslo University Hospital:
Uro-genital schistosomiasis
Female
South Africa
Rural
Sexually transmitted diseases
Additional relevant MeSH terms:
Layout table for MeSH terms
Schistosomiasis haematobia
Schistosomiasis
Trematode Infections
Helminthiasis
Parasitic Diseases
Urinary Tract Infections
 Infection
Urologic Diseases
Praziquantel
Anthelmintics
Antiparasitic Agents
Anti-Infective Agents